PHARMACEUTICAL IP

  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us

Evolve Insights

Welcome to Evolve Insights!

Evolve Insights is your go-to source for expert analysis and strategic perspectives on pharmaceutical IP.

  • Read our Articles for the latest pharma IP news and analysis. Many of our articles were originally published on IPKat.
  • Register for our upcoming live Webinars and watch our previous webinars on-demand.
  • Subscribe to our newsletter to stay up to date.

Do you have questions about how the latest developments in IP might impact you? Our team of experts would love to hear from you.

Latest articles

All articles

Evolve’s Claudia Greaves earns CIPA Advanced Patent Paralegal Qualification

  • 9th January 2026
We are delighted to announce that Evolve’s Claudia Greaves, has recently passed the CIPA Advanced Patent Paralegal Course (APPC). Building on her six years of patent law experience, Claudia completed intensive modules that deepen her expertise in critical areas of IP management: The Patent Cooperation Treaty (PCT): Gaining in-depth understanding of both the International Phase…

Strict US written description and enablement requirement applied to ADCs and platform inventions (Seagen v Daiichi Sankyo)

  • 14th December 2025
The recent decision of the US Court of Appeals for the Federal Circuit in Seagen v. Daiichi Sankyo overruled the jury decision in the District Court to find an ADC linker platform patent invalid for both lack of written description and enablement. 

ViCo oral proceedings: Whatever happened to the in-person “Gold-Standard”?

  • 14th December 2025
We are now many years on from the pandemic conditions that initially led to the introduction of oral proceedings by video conferencing for Board of Appeal cases. But what happened to the “Gold Standard” of in-person proceedings promised by the EBA in G 1/21? 

Webinars

All webinars
  • Upcoming

In-person event: Festive EPO pharma case law 2025 round-up

Upcoming date: December 17, 2025, 4:00 pm GMT
Join us for a wrap up review of the key pharma EPO caselaw in 2025 and a look ahead to 2026 alongside some mince pies and festive cheer.
  • On-demand

EPO pharma case law 2025: Everything you need to know!

Recorded on: December 12, 2025
Key pharma IP trends, landmark EPO decisions, and strategic advice for IP professionals.
  • On-demand

Securing return of investment: Understanding how large pharma companies think about IP

Recorded on: September 19, 2025
Learn how large pharmaceutical companies think about IP strategy.
Previous Next

Stay connected

Get the latest insights, news, and expert analysis on pharmaceutical IP delivered straight to your inbox.
Subscribe for updates

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

Subscribe

Contact Us